| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/24/2009 | CA2356745C Ionic aqueous composition containing levomenthol |
| 03/24/2009 | CA2352211C Sustained release matrix systems for highly soluble drugs |
| 03/24/2009 | CA2351203C 2,4-disubstituted triazine derivatives with anti hiv activity |
| 03/24/2009 | CA2348579C Azadirachtin compounds extracted from azadirachta indica, compositions and use thereof as insecticidal |
| 03/24/2009 | CA2345896C A method of modulating ion channel functional activity |
| 03/24/2009 | CA2338703C Injectable aqueous dispersions of propofol |
| 03/24/2009 | CA2336628C Method for reducing the damaging effects of radiation therapy on animal skin and mucosa |
| 03/24/2009 | CA2320717C Method for the treatment of diseases or disorders of the inner ear |
| 03/24/2009 | CA2319099C Compositions and methods of treating keratin-related disorders and conditions |
| 03/24/2009 | CA2264626C Pharmaceutical composition containing lornoxicam and a disodium salt of edta |
| 03/24/2009 | CA2224060C Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| 03/24/2009 | CA2223513C Betulinic acid derivatives and uses therefor |
| 03/24/2009 | CA2176373C Farnesyl derivatives and pharmaceutical compositions containing them |
| 03/24/2009 | CA2136969C Prevention and treatment of peripheral neuropathy |
| 03/19/2009 | WO2009036428A2 1,3,4-trisubstituted benzenes |
| 03/19/2009 | WO2009036412A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 03/19/2009 | WO2009036407A2 Compositions and methods for regulating cellular protection |
| 03/19/2009 | WO2009036341A2 Compositions and methods relating to hiv protease inhibition |
| 03/19/2009 | WO2009036322A1 Use of propofol prodrugs for treating neuropathic pain |
| 03/19/2009 | WO2009036287A1 Dosing regimen |
| 03/19/2009 | WO2009036281A2 Bortezomib and process for producing same |
| 03/19/2009 | WO2009036257A1 Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype |
| 03/19/2009 | WO2009036243A1 Novel combination of therapeutic agents |
| 03/19/2009 | WO2009036144A1 Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| 03/19/2009 | WO2009036132A1 Octahydro-pyrrolo[3,4-b]pyrrole n-oxides |
| 03/19/2009 | WO2009036117A1 Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists |
| 03/19/2009 | WO2009036108A1 Methods and compositions for inhibiting vascular leakage |
| 03/19/2009 | WO2009036106A1 Cytotoxic xanthone compounds |
| 03/19/2009 | WO2009036099A1 A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| 03/19/2009 | WO2009036082A2 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| 03/19/2009 | WO2009036068A2 Gambogic amine, a selective trka agonist with neuroprotective activity |
| 03/19/2009 | WO2009036066A1 Vegfr inhibitors containing a zinc binding moiety |
| 03/19/2009 | WO2009036059A2 Novel stat3 pathway inhibitors and cancer stem cell inhibitors |
| 03/19/2009 | WO2009036057A1 Antiproliferative agents containing a zinc binding moiety |
| 03/19/2009 | WO2009036055A1 Vegfr inhibitors containing a zinc binding moiety |
| 03/19/2009 | WO2009036051A1 Bcl-2 inhibitors containing a zinc binding moiety |
| 03/19/2009 | WO2009036035A1 Bcl-2 inhibitors |
| 03/19/2009 | WO2009036020A1 Mek inhibitors containing a zinc binding moiety |
| 03/19/2009 | WO2009036016A1 Cdk inhibitors containing a zinc binding moiety |
| 03/19/2009 | WO2009036000A2 Methods of treating a microbial infection by modulating rnase-l expression and/or activity |
| 03/19/2009 | WO2009035997A2 Benzo-fused heterocycles |
| 03/19/2009 | WO2009035987A1 METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE. α-AMYLASE AND α-GLUCOSIDASE ACTIVITY IN MAMMALS |
| 03/19/2009 | WO2009035969A1 Process for the preparation of compounds useful as inhibitors of sglt |
| 03/19/2009 | WO2009035951A2 Soluble epoxide hydrolase inhibitors |
| 03/19/2009 | WO2009035949A2 Soluble epoxide hydrolase inhibitors |
| 03/19/2009 | WO2009035929A2 Cardiovascular and brain cell therapy using intracellular ryanodine receptor modulation by the estrogen receptor beta |
| 03/19/2009 | WO2009035928A1 Soluble epoxide hydrolase inhibitors |
| 03/19/2009 | WO2009035927A2 Bis-cyclyl substituted ureas or amides as soluble epoxide hydrolase inhibitors |
| 03/19/2009 | WO2009035908A1 Compositions and their use for the treatment of protozoal infections comprising metaflumi zone |
| 03/19/2009 | WO2009035855A2 Novel uses of halogenated alkyl sulfonamides |
| 03/19/2009 | WO2009035818A1 Compounds that modulate intracellular calcium |
| 03/19/2009 | WO2009035788A1 Alkylsulfonyl-substituted thiazolide compounds |
| 03/19/2009 | WO2009035743A2 Borated concrete-rubber |
| 03/19/2009 | WO2009035718A1 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety |
| 03/19/2009 | WO2009035684A1 Spirocyclic aminoquinolones as gsk-3 inhibitors |
| 03/19/2009 | WO2009035673A1 Compositions and methods for treating macular degeneration |
| 03/19/2009 | WO2009035671A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor |
| 03/19/2009 | WO2009035662A1 Deuterated 4 -oxoquinoline derivatives for the treatment of hiv infection |
| 03/19/2009 | WO2009035652A1 Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
| 03/19/2009 | WO2009035634A2 Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors |
| 03/19/2009 | WO2009035598A1 Deuterated pirfenidone |
| 03/19/2009 | WO2009035575A1 Inhibitors of janus kinases |
| 03/19/2009 | WO2009035568A1 Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| 03/19/2009 | WO2009035565A1 Prostaglandin analogues for implant devices and methods |
| 03/19/2009 | WO2009035553A2 Analogs of tetramic acid |
| 03/19/2009 | WO2009035550A1 Treating patients with subarachnoid hemorrhage |
| 03/19/2009 | WO2009035543A1 Dual-acting antihypertensive agents |
| 03/19/2009 | WO2009035540A2 Analogues of exendin-4 and exendin-3 |
| 03/19/2009 | WO2009035539A2 Long interfering nucleic acid duplexes targeting multiple rna targets |
| 03/19/2009 | WO2009035534A2 Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| 03/19/2009 | WO2009035527A2 Levonorgestrel crystallization |
| 03/19/2009 | WO2009035474A1 Abuse resistant drug formulation |
| 03/19/2009 | WO2009035473A2 Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
| 03/19/2009 | WO2009035438A1 Polymeric nanoparticles by ion-ion interactions |
| 03/19/2009 | WO2009035387A1 A medicament prepared using methotrexate and suitable for topical administration, for the treatment of a lower gastrointestinal tract inflammatory disease |
| 03/19/2009 | WO2009035368A1 Antidiabetic pharmaceutical composition |
| 03/19/2009 | WO2009035265A2 Calcium phosphate microspheres drug delivery system and process for preparing the same |
| 03/19/2009 | WO2009035253A2 Novel use of scoparone |
| 03/19/2009 | WO2009035251A1 Novel use of dimethylfumarate |
| 03/19/2009 | WO2009035174A1 Composition for treating or preventing atopic dermatitis comprising poly-gamma-glutamic acid |
| 03/19/2009 | WO2009035173A1 Composition for preventing virus infection comprising poly-gamma-glutamic acid |
| 03/19/2009 | WO2009035168A1 Sulfonic acid salt compound of 4-carbamoyl-5-hydroxy-imidazole derivative |
| 03/19/2009 | WO2009035162A1 6-pyrimidinyl-pyrimid-2-one derivative |
| 03/19/2009 | WO2009035159A1 3-methyl-2- ( (2s) -2- (4- (3-methyl-1, 2, 4-oxadiazol-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor |
| 03/19/2009 | WO2009035157A1 Therapeutic and/or prophylactic agent for lower urinary tract symptoms after radiotherapy |
| 03/19/2009 | WO2009035156A1 Novel compound, process for production thereof, and use thereof |
| 03/19/2009 | WO2009035068A1 Novel 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1h-quinoxalin- 2-one derivatives |
| 03/19/2009 | WO2009035067A1 Glucocorticoid receptor agonists consisting of 1,3,3-tri- methyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivatives |
| 03/19/2009 | WO2009035034A1 Ophthalmic composition |
| 03/19/2009 | WO2009035033A1 Ophthalmic composition |
| 03/19/2009 | WO2009035020A1 Novel dihydronaphthalene compound and use thereof |
| 03/19/2009 | WO2009035004A1 Substituted isoxazoline compound and pest control agent |
| 03/19/2009 | WO2009034976A1 Alkylsulfone derivative |
| 03/19/2009 | WO2009034945A1 Medicinal agent for disease associated with epstein-barr virus, and method for screening of the medicinal agent |
| 03/19/2009 | WO2009034581A1 Substituted indolyl compounds and their use as 5-ht6 ligands |
| 03/19/2009 | WO2009034541A2 Controlled release pharmaceutical dosage forms of trimetazidine |
| 03/19/2009 | WO2009034540A1 Pharmaceutical composition of sevelamer |
| 03/19/2009 | WO2009034537A2 Cosmetic composition comprising hydroxymethionine and 3-aminopropanesulfonic acid |
| 03/19/2009 | WO2009034475A2 Perharidines as cdk inhibitors |
| 03/19/2009 | WO2009034458A2 Oxygen permeable polymeric nanocontainers for encapsulation of sensitive compounds |